NutriKane D available here



The key target markets for NutriKane+ are Private and Public Hospitals with secondary targets being Aged Care Facilities, Rehabilitation Care and Convalescent Homes. 

Opioid Induced Constipation (OIC) is the most common side effect of prolonged opioid use. Doctors prescribe opioid drugs for pain management in patients following surgery and they are extremely effective for pain management. However, OIC prolongs the length of patient hospital stays and increases patient discomfort, the aggregate cost of treatment and hospital waiting times.

The condition is so widespread that pharma giants AstraZeneca and Daiichi Sankyo funded a constipation awareness advertisement during the 2016 Super Bowl in response to America’s growing opioid addiction crisis. Both companies have spent hundreds of millions of dollars to purchase the rights to a ‘first-of-kind’ constipation drug for painkiller users that includes in its list of side effects ‘allergic reaction, hives, difficulty breathing, facial swelling, severe stomach pain, severe diarrhea, symptoms of narcotic medicine withdrawal, anxiety, feeling irritable, sweating, chills, nausea, vomiting and headache'. NutriKane+ displays none of these side effects. It is perfectly safe without risk of overdose. We just need to tell people about it.

General constipation (chronic) affects a considerable proportion of the population. The incidence of constipation increases with age as both gut and bowel health begin to deteriorate. Recent studies have shown that 16% of Americans and a third of those over the age of 60 suffer from chronic constipation. That is 50 million Americans. It has resulted in more than 700,000 hospital visits per year at a cost of USD $1.7 billion (2011). The economic cost of chronic constipation worldwide is significant. Billions of dollars are spent annually on treatment for a highly treatable ‘lifestyle’ condition.


MediKane’s own clinical trials show that the rate of constipation for the elderly living in care is between 50% and 75%, caused by deteriorating gut and bowel health.

Three key areas of use for NutriKane+ are being actively pursued:

  • Pre-operative patients – intestinal and bowel health (as currently used in an Illinois hospital group)
  • Post-operative patients – faster resumption of normal intestinal and bowel function
  • On-going care for rehabilitation patients and aged care residents – intestinal and bowel health

While the problem is worldwide, the focus for MediKane has been in Australia and in the USA, where private hospitals and facilities have an incentive to optimise cost management by improving the availability of beds. 

NutriKane+ is a commercial Business to Business (B2B) product. Target markets are to sell directly to hospitals and care facilities. Hospitals in the USA have completed clinical trials of NutriKane+. The product is ready to launch in this market. MediKane’s clinical partner has prepared a NutriKane presentation for wide dissemination but COVID-19 has slowed that initiative.

The accessible market for NutriKane+ is defined as people in hospitals or aged care facilities with constipation, using oral drugs, looking for natural medications and who can access the product (i.e. part of a good distribution network).




NutriKane+ is a natural option for intestinal health maintenance that assists with regular laxation and contributes to the relief of constipation in managed care facilities. NutriKane+ is a natural functional food that has been clinically shown to perform and exceed the capabilities of currently used products.

NutriKane+ featured in two published trials in 2015. The results showed that NutriKane+ was easy to use and an effective agent for regularity maintenance in managed care patients. The Royal Melbourne Hospital trial specifically targeting the effects of intestinal health in managed care facilities resulted in overwhelming positive outcomes. 85% of patients reported improvement to digestive health and laxation on medical standard measures. In 60% of cases patients were already using some form of laxative without success. The Spina Bifida trial demonstrates the value when working with individuals that suffer from chronically compromised digestion. Significantly, NutriKane+ was reported to maintain regularity even with use of opioid analgesics.